WHF Roadmap on Single Pill Combination Therapies

Enrico G. Ferro; Gautam Satheesh; José Castellano; Albertino Damasceno; Okeoma Erojikwe; Mark Huffman; Vilma Irazola; Philip Joseph; Fernando Lanas; Elijah Ogola; Pedro Ordunez; Pablo Perel; Daniel Pineiro; Izabela Uchmanowicz; Orly Vardeny; Ruth Webster; Habib Gamra; Thomas Gaziano; Adrianna Murphy

doi:10.5334/gh.1457

WHF Roadmap on Single Pill Combination Therapies

Volume 20 (2025): Issue 1

By: Enrico G. Ferro , Gautam Satheesh , José Castellano , Albertino Damasceno , Okeoma Erojikwe , Mark Huffman , Vilma Irazola , Philip Joseph, Fernando Lanas , Elijah Ogola , Pedro Ordunez , Pablo Perel , Daniel Pineiro , Izabela Uchmanowicz , Orly Vardeny , Ruth Webster , Habib Gamra , Thomas Gaziano and Adrianna Murphy

Open Access

|Aug 2025

Abstract

Cardiovascular diseases (CVDs) are the leading global cause of mortality, with treatment adherence posing a major barrier to effective prevention and control. Single pill combinations (SPCs), also known as fixed-dose combinations, simplify treatment by combining multiple agents into one pill, improving adherence and reducing cardiovascular risk. This World Heart Federation Roadmap synthesizes the latest clinical evidence and identifies key barriers to SPC implementation, including limited manufacturing, affordability, regulatory complexity, and inconsistent guideline inclusion. Drawing on global expert input and health systems analysis, the Roadmap outlines practical, context-specific solutions to improve access, scale-up, and integration of SPCs into national strategies, especially in low- and middle-income countries. It serves as a tool for policymakers, clinicians, and advocates to drive progress in aligning cardiovascular prevention efforts with evidence-based, people-centred care.

References

Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The Heart of the World. Glob Heart. 2024;19(1):11. DOI: 10.5334/gh.1288
Open DOI Search in Google Scholar Back to article
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Bmj. 2003;326(7404):1419. DOI: 10.1136/bmj.326.7404.1419
Open DOI Search in Google Scholar Back to article
Katzmann JL, Sorio-Vilela F, Dornstauder E, Fraas U, Smieszek T, Zappacosta S, et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. 2022;111(3):243–52. DOI: 10.1007/s00392-020-01740-8
Open DOI Search in Google Scholar Back to article
Banach M, Jaiswal V, Ang SP, Sawhney A, Deb N, Amarenco P, et al. Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis. Mayo Clin Proc. 2025. DOI: 10.1016/j.mayocp.2025.01.018
Open DOI Search in Google Scholar Back to article
Campbell NRC. A step in the global effort to control hypertension: Fixed dose combination antihypertensive drugs. J Clin Hypertens (Greenwich). 2019.21(9):1426–8. DOI: 10.1111/jch.13683
Open DOI Search in Google Scholar Back to article
Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125–36. DOI: 10.5114/aoms.2018.77561
Open DOI Search in Google Scholar Back to article
Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021–31. DOI: 10.1056/NEJMoa1600176
Open DOI Search in Google Scholar Back to article
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–83. DOI: 10.1016/S0140-6736(19)31791-X
Open DOI Search in Google Scholar Back to article
Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216–28. DOI: 10.1056/NEJMoa2028220
Open DOI Search in Google Scholar Back to article
Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967–77. DOI: 10.1056/NEJMoa2208275
Open DOI Search in Google Scholar Back to article
Agarwal A, Mehta PM, Jacobson T, Shah NS, Ye J, Zhu J, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med. 2024;30(4):1199–209. DOI: 10.1038/s41591-024-02896-w
Open DOI Search in Google Scholar Back to article
Agarwal A, Mehta PM, Jacobson T, Shah NS, Ye J, Zhu J, et al. Author Correction: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med. 2024;30(8):2371. DOI: 10.1038/s41591-024-03128-x
Open DOI Search in Google Scholar Back to article
Gaziano TA, Pandya A, Sy S, Jardim TV, Ogden JM, Rodgers A, et al. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019;214:77–87. DOI: 10.1016/j.ahj.2019.04.020
Open DOI Search in Google Scholar Back to article
Jahangiri R, Rezapour A, Malekzadeh R, Olyaeemanesh A, Roshandel G, Motevalian SA. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review. PLoS One. 2022;17(7):e0271908. DOI: 10.1371/journal.pone.0271908
Open DOI Search in Google Scholar Back to article
Lamy A, Tong W, Joseph P, Gao P, Huffman MD, Roshandel G, et al. Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis. EClinicalMedicine. 2024;73:102651. DOI: 10.1016/j.eclinm.2024.102651
Open DOI Search in Google Scholar Back to article
O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761–75. DOI: 10.1016/S0140-6736(16)30506-2
Open DOI Search in Google Scholar Back to article
Agarwal A, Yancy CW, Huffman MD. Improving Care for Heart Failure With Reduced Ejection Fraction-A Potential Polypill-Based Strategy. Jama. 2020;324(22):2259–60. DOI: 10.1001/jama.2020.21395
Open DOI Search in Google Scholar Back to article
Pandey A, Keshvani N, Wang TJ. Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction? Circulation. 2022;146(4):276–8. DOI: 10.1161/CIRCULATIONAHA.122.059661
Open DOI Search in Google Scholar Back to article
Vijay A, Tay WT, Teng TK, Teramoto K, Tromp J, Ouwerkerk W, et al. Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis. Glob Heart. 2023;18(1):33. DOI: 10.5334/gh.1215
Open DOI Search in Google Scholar Back to article
Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. Jama. 2013;310(9):918–29. DOI: 10.1001/jama.2013.277064
Open DOI Search in Google Scholar Back to article
Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Bmj. 2014;348:g3318. DOI: 10.1136/bmj.g3318
Open DOI Search in Google Scholar Back to article
Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920–30. DOI: 10.1177/2047487314530382
Open DOI Search in Google Scholar Back to article
Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133–46. DOI: 10.1016/S0140-6736(21)01827-4
Open DOI Search in Google Scholar Back to article
Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. 2016;205:147–56. DOI: 10.1016/j.ijcard.2015.12.015
Open DOI Search in Google Scholar Back to article
Sarfo FS, Voeks J, Adamu S, Agyei BA, Agbenorku M, Adu-Darko N, et al. A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial. Lancet Glob Health. 2023;11(10):e1619–e28. DOI: 10.1016/S2214-109X(23)00347-9
Open DOI Search in Google Scholar Back to article
Watkins DA, Pickersgill SJ, Flood D, Gaziano TA, Huffman MD, Islam S, et al. Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023–2050: A Modeling Study. J Am Coll Cardiol. 2025;86(3):149–61. DOI: 10.1016/j.jacc.2025.04.043
Open DOI Search in Google Scholar Back to article
Mohamed MG, Osman M, Kheiri B, Saleem M, Lacasse A, Alkhouli M. Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2022;360:91–8. DOI: 10.1016/j.ijcard.2022.04.085
Open DOI Search in Google Scholar Back to article
Memon RA, Raveena Bai B, Simran F, Kumari M, Aisha F, Sai Kiran K, et al. Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Cureus. 2023;15(1):e34134. DOI: 10.7759/cureus.34134
Open DOI Search in Google Scholar Back to article
Lopez-Lopez JP, Gonzalez AM, Lanza P, Lopez-Jaramillo P. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. Vasc Health Risk Manag. 2023;19:605–15. DOI: 10.2147/VHRM.S421024
Open DOI Search in Google Scholar Back to article
The Lancet. Polypills: an essential medicine for cardiovascular disease. Lancet. 2017;389(10073):984. DOI: 10.1016/S0140-6736(17)30695-5
Open DOI Search in Google Scholar Back to article
Frost LJ, Reich MR. Creating access to health technologies in poor countries. Health Aff (Millwood). 2009.28(4):962–73. DOI: 10.1377/hlthaff.28.4.962
Open DOI Search in Google Scholar Back to article
Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health Policy and Planning. 2012;28(7):692–704. DOI: 10.1093/heapol/czs108
Open DOI Search in Google Scholar Back to article
Vledder M, Friedman J, Sjöblom M, Brown T, Yadav P. Improving Supply Chain for Essential Drugs in Low-Income Countries: Results from a Large Scale Randomized Experiment in Zambia. Health Syst Reform. 2019;5(2):158–77. DOI: 10.1080/23288604.2019.1596050
Open DOI Search in Google Scholar Back to article
Organization WH. Antiretroviral medicines in low- and middle-income countries: forecasts of global and regional demand for 2020–2024; 2022.
Search in Google Scholar Back to article
Satheesh G, Gyawali B, Sun MFC, Huffman MD, Banerjee A, Perel P, et al. A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries. Glob Heart. 2024;19(1):56. DOI: 10.5334/gh.1335
Open DOI Search in Google Scholar Back to article
DRL’s Red Heart Pill off R&D shelves. The New Indian Express. 2013; 15 February 2013.
Search in Google Scholar Back to article
Liu H, Huffman MD, Trieu K. The role of contextualisation in enhancing non-communicable disease programmes and policy implementation to achieve health for all. Health Res Policy Syst. 2020;18(1):38. DOI: 10.1186/s12961-020-00553-5
Open DOI Search in Google Scholar Back to article
Rodgers A, Smith R. The polypill and medicines access: two decades and counting. Bmj. 2023;382:1847. DOI: 10.1136/bmj.p1847
Open DOI Search in Google Scholar Back to article
Mitra A, Wu Y. Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. Aaps j. 2012;14(3):646–55. DOI: 10.1208/s12248-012-9378-x
Open DOI Search in Google Scholar Back to article
(CDER) USDoHaHSFaDACfDEaR. Hypertension: Developing Fixed-Combination Drug Products for Treatment. Guidance for Industry. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm2018.
Search in Google Scholar Back to article
European Medicines Agency. Guideline on clinical development of fixed combination medicinal products. 2017.
Search in Google Scholar Back to article
Ren W, Zhao Y, Zhong H, Fu X, Wu J. Exploring the Optimal Allocation Decision-Making of Expenditure Budget in Hospitals Under Multi-Objective Constraints: Evidence from Urban Public Hospitals, China. SAGE Open. 2021;11(4):21582440211058191. DOI: 10.1177/21582440211058191
Open DOI Search in Google Scholar Back to article
Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Glob Health. 2020;5(11). DOI: 10.1136/bmjgh-2020-002640
Open DOI Search in Google Scholar Back to article
Murphy A, Palafox B, Walli-Attaei M, Powell-Jackson T, Rangarajan S, Alhabib KF, et al. The household economic burden of non-communicable diseases in 18 countries. BMJ Glob Health. 2020;5(2):e002040. DOI: 10.1136/bmjgh-2019-002040
Open DOI Search in Google Scholar Back to article
Negi S, Neupane D, Sahoo SK, Mahajan T, Swaroop K, Moran AE, et al. Prices of combination medicines and single-molecule antihypertensive medicines in India’s private health care sector. J Clin Hypertens (Greenwich). 2021;23(4):738–43. DOI: 10.1111/jch.14143
Open DOI Search in Google Scholar Back to article
Becerra V, Gracia A, Desai K, Abogunrin S, Brand S, Chapman R, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015;5(5):e007111. DOI: 10.1136/bmjopen-2014-007111
Open DOI Search in Google Scholar Back to article
Lin JK, Moran AE, Bibbins-Domingo K, Falase B, Pedroza Tobias A, Mandke CN, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. Lancet Glob Health. 2019;7(10):e1346–e58. DOI: 10.1016/S2214-109X(19)30339-0
Open DOI Search in Google Scholar Back to article
Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. PLoS One. 2015;10(10):e0140708. DOI: 10.1371/journal.pone.0140708
Open DOI Search in Google Scholar Back to article
Beall RF, Schwalm JD, Huffman MD, McCready T, Yusuf S, Attaran A. Could patents interfere with the development of a cardiovascular polypill? J Transl Med. 2016;14(1):242. DOI: 10.1186/s12967-016-0997-3
Open DOI Search in Google Scholar Back to article
Marklund M, Mattingly Ii TJ, Sahoo SK, Kaur P, Moran AE, Appel LJ, et al. Effects of medication procurement reforms and extended prescription duration on medication coverage for hypertension in India’s public health system: a modelling study. BMJ Public Health. 2025;3(1):e001044. DOI: 10.1136/bmjph-2024-001044
Open DOI Search in Google Scholar Back to article
Bazargani YT, Ewen M, de Boer A, Leufkens HG, Mantel-Teeuwisse AK. Essential medicines are more available than other medicines around the globe. PLoS One. 2014;9(2):e87576. DOI: 10.1371/journal.pone.0087576
Open DOI Search in Google Scholar Back to article
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. DOI: 10.1097/HJH.0000000000003480
Open DOI Search in Google Scholar Back to article
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(38):3720–826. DOI: 10.1093/eurheartj/ehad191
Open DOI Search in Google Scholar Back to article
Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. J Am Heart Assoc. 2020;9(9):e015302. DOI: 10.1161/JAHA.119.015302
Open DOI Search in Google Scholar Back to article
Liu H, Massi L, Laba TL, Peiris D, Usherwood T, Patel A, et al. Patients’ and providers’ perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial. Circ Cardiovasc Qual Outcomes. 2015;8(3):301–8. DOI: 10.1161/CIRCOUTCOMES.115.001483
Open DOI Search in Google Scholar Back to article
Salam A, Praveen D, Patel A, Tewari A, Webster R. Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study. Glob Heart. 2019;14(3):303–10. DOI: 10.1016/j.gheart.2019.07.002
Open DOI Search in Google Scholar Back to article
Lewis PJ, Tully MP. Uncomfortable prescribing decisions in hospitals: the impact of teamwork. J R Soc Med. 2009;102(11):481–8. DOI: 10.1258/jrsm.2009.090150
Open DOI Search in Google Scholar Back to article
Brax H, Fadlallah R, Al-Khaled L, Kahale LA, Nas H, El-Jardali F, et al. Association between physicians’ interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. PLoS One. 2017;12(4):e0175493.
Search in Google Scholar Back to article
Virdee SK, Greenfield SM, Fletcher K, McManus RJ, Hobbs FDR, Mant J. Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open. 2013;3(3):e002498. DOI: 10.1136/bmjopen-2012-002498
Open DOI Search in Google Scholar Back to article
O’Hagan E, McIntyre D, Nguyen T, Tan KM, Hanlon P, Siddiqui M, et al. A Cross-Sectional Survey of Fixed-Dose Combination Antihypertensive Medicine Prescribing in Twenty-Four Countries, Including Qualitative Insights. Global Heart. 2024. DOI: 10.5334/gh.1353
Open DOI Search in Google Scholar Back to article
Giron N, Lim C, Vallini J, Hallar K. Moving toward improved access to medicines and health technologies for cardiovascular disease. Rev Panam Salud Publica. 2023;47:e93. DOI: 10.26633/RPSP.2023.93
Open DOI Search in Google Scholar Back to article
Rodgers A, Satheesh G, Murphy A. The Potential of Single Pill Combinations. J Am Coll Cardiol. 2025;86(3):162–4. DOI: 10.1016/j.jacc.2025.06.006
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.5334/gh.1457 | Journal eISSN: 2211-8179

Journal RSS Feed

Language: English

Submitted on: Jul 25, 2025

Accepted on: Jul 30, 2025

Published on: Aug 29, 2025

Published by: Ubiquity Press

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

Cardiovascular disease,

single pill combinations,

prevention,

polypill

© 2025 Enrico G. Ferro, Gautam Satheesh, José Castellano, Albertino Damasceno, Okeoma Erojikwe, Mark Huffman, Vilma Irazola, Philip Joseph, Fernando Lanas, Elijah Ogola, Pedro Ordunez, Pablo Perel, Daniel Pineiro, Izabela Uchmanowicz, Orly Vardeny, Ruth Webster, Habib Gamra, Thomas Gaziano, Adrianna Murphy, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 20 (2025): Issue 1